Patients ( N = @ ; age , @ y ) with moderate-to-severe active Crohn 's disease were assigned randomly to groups given @ mg ( n = @ ) , @ mg ( n = @ ) , or @ mg ( n = @ ) tofacitinib or placebo ( n = @ ) , twice daily for @ weeks , at @ centers in @ countries .